Chemical FBXO7 Inhibition for PINK1 Stabilization and Neuroprotection

The patent uses small molecule compounds as intermediaries to disrupt the interaction between Fbxo7 and Pink1. These compounds bind to Fbxo7 and prevent it from recruiting Pink1 to the ubiquitin-proteasome system, thereby stabilizing Pink1 without directly targeting the proteasome itself. This intermediary approach resolves the contradiction by blocking the degradation pathway while preserving normal cellular functions.

The patent changes the binding parameters of the Fbxo7-Pink1 interaction by introducing small molecule compounds that alter the affinity or conformation of Fbxo7. By modifying these molecular parameters, the compounds prevent Pink1 degradation while maintaining other physiological functions of Fbxo7, thus increasing Pink1 levels without causing mitochondrial dysfunction.

The patent introduces small molecule compounds as intermediaries that indirectly increase Pink1 levels by blocking its degradation. Rather than attempting to directly synthesize or stabilize Pink1 protein (which would be complex), the compounds mediate the effect by interfering with the Fbxo7-mediated degradation pathway, providing a practical chemical solution where none previously existed.

The patent replaces the complex biological regulation of Pink1 stability with a simple small molecule intervention. Instead of relying on natural regulatory mechanisms or complex genetic manipulation, the compounds provide a straightforward chemical means to increase Pink1 levels, making the approach manufacturable and clinically applicable.